



## Recent Advances in Chimeric Antigen Receptor Technology

Guest Editor:

**Dr. Matthias Hardtke-  
Wolenski**

Department of Gastroenterology,  
Hepatology & Endocrinology,  
Hannover Medical School, 30625  
Hannover, Germany

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editor

Immunotherapies play an increasingly important role as a therapeutic option for a broad spectrum of diseases, ranging from cancer to autoimmunity. The two main modulations can be summarized by antibody therapies or adoptive cell transfer. Here, the idea of using chimeric antigen receptors (CARs) to produce modified cells is taking an increasingly important place. CARs recognize their antigen without the limitations of MHC II restriction.

Over the past decade, the continuous development of next-generation CARs has been outstanding. There are many options for CAR therapies. While the first trials started with cancer, autoimmunity was quickly added. Today, antifibrotic CAR therapies are also feasible. Additionally, the various possibilities in adapting CARs to their targets have been widely used. The target cells vary from T cells to regulatory T cells and natural killer cells.

In this Special Issue, we would like to collect recent publications on the research results and knowledge related to CAR technology.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI